Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Spinal Diseases: HELP
Articles by Giacomo Cafaro
Based on 2 articles published since 2009
(Why 2 articles?)
||||

Between 2009 and 2019, Giacomo Cafaro wrote the following 2 articles about Spinal Diseases.
 
+ Citations + Abstracts
1 Review Psoriatic arthritis: tissue-directed inflammation? 2018

Cafaro, Giacomo / McInnes, Iain B. ·Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy. giacomo.cafaro@libero.it. · Institute of Infection Immunity and Inflammation, College of MVLS, University of Glasgow, Glasgow, G128QQ, UK. ·Clin Rheumatol · Pubmed #29476352.

ABSTRACT: The clinical picture of psoriatic arthritis (PsA) is heterogeneous, potentially involving numerous organs and tissues, such as skin and joint. From a clinical point of view, discrete tissue PsA features develop and respond to treatments apparently independently. The pathogenic events occurring in the various tissues are only partially understood. Although the vast majority of known genetic predisposing factors are shared between patients with skin psoriasis (PSO) and those affected by PsA, some tissue-specific variants have been identified. Furthermore, current data suggest that the TNF pathway and IL-23/Th17 pathways may be differentially activated in distinct tissue sites. In this review, we briefly describe current knowledge on the pathogenesis of PsA in terms of genetic predisposition, environmental factors and immunology, advancing our hypothesis to explain why a common immunologic process can express itself with significant differences in various tissues.

2 Review Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis. 2015

Alunno, Alessia / Carubbi, Francesco / Cafaro, Giacomo / Pucci, Giacomo / Battista, Francesca / Bartoloni, Elena / Giacomelli, Roberto / Schillaci, Giuseppe / Gerli, Roberto. ·a 1 University of Perugia, Department of Medicine , Perugia, Italy. · b 2 University of L'Aquila, Rheumatology Unit, Department of Biotechnological and Applied Clinical Sciences , L'Aquila, Italy. · c 3 Terni University Hospital, Unit of Internal Medicine , piazzale Tristano di Joannuccio 1, Terni, Italy +39 07 44 20 52 01 ; giuseppe.schillaci@unipg.it. ·Expert Opin Biol Ther · Pubmed #26653110.

ABSTRACT: INTRODUCTION: A growing amount of data supporting the pathogenic role of the IL-23/IL-17 axis in inflammatory/autoimmune disorders has provided the rationale to target the system for therapeutic purpose. Several compounds have been and are currently under intense investigation in psoriasis and psoriatic arthritis (PsA) yielding impressive results. AREAS COVERED: In this review article, we provide an overview of currently available data on the IL-23/IL-17 system as a target for treatment for psoriasis and PsA. We searched MEDLINE for articles on drug therapy for psoriasis and PsA published between 1 January 2010 and 31 May 2015. One of these agents, ustekinumab, has been recently approved for the treatment of psoriasis and PsA, and a number of IL-23/IL-17-targeted compounds under investigation in these diseases. EXPERT OPINION: As our knowledge of the role of the IL-23/IL-17 axis in the pathogenesis of psoriasis and PsA deepens, it enables the development of more targeted therapies in the management of these conditions. Early data on IL-23/IL-17 targeting drugs appear promising, although incomplete. Given the key role IL-23/IL-17 in host defence, the safety profile of targeted drugs should be thoroughly assessed in future studies.